Work

S1PR3–G12-biased agonist ALESIA targets cancer metabolism and promotes glucose starvation

Year: 2021

Type: article

Source: Cell chemical biology

DOI: 10.1016/j.chembiol.2021.01.004

Authors: Masayasu Toyomoto, Asuka Inoue, Kei Iida, Masatsugu Denawa, Isao Kii, Francois Marie Ngako Kadji, Takayuki Kishi, Dohyun Im, Tatsuro Shimamura, Hiroshi Onogi, Suguru Yoshida, So Iwata, Junken Aoki, Takamitsu Hosoya, Masatoshi Hagiwara

Institutions: Kyoto University, Tohoku University, Shinshu University, Tokyo Medical and Dental University, The University of Tokyo

Language: English

Topic: Sphingolipid Metabolism and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, Japan Society for the Promotion of Science, Japan Science and Technology Agency, Core Research for Evolutional Science and Technology, Precursory Research for Embryonic Science and Technology

Awards: G1443885606, スプライシング操作化合物を対象としたファーマコゲノミクス解析に基づく遺伝性難病治療薬の開発研究, Gタンパク質共役型受容体の活性化に影響を及ぼす代謝物の同定, G352700090, Challenges to the structural change analysis of G Protein-Coupled Receptors, Drug discovery targeting folding intermediates of kinases, G4445044908, G6036565778, Biased GPCR signaling mechanism, G6609757852, G6618751941, Structural analysis of amine receptors for the development of new antipsychotic drugs., G671860764, Establishing key technologies for structure-based design of medium-sized therapeutic molecules targeting human membrane proteins, G7480707513, G7656821920, G8140675031, G8401814264, パーキンソン病治療を可能とするiPS創薬研究, 京都大学臨床研究ハイウェイを活用した難治疾患・がん等の新規治療法の開発(H24-実用化(国際)-指定-003)

OpenAlex ID: W3128317280

FWCI: 0.561

Cites: 84

Cited by: 14

Related to: 10